Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 Business Wire - Thu Apr 23, 6:30AM CDT

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference...

VSTM : 5.46 (-1.44%)
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers Business Wire - Fri Apr 10, 6:00AM CDT

Patients in the Phase 2 RAMP 201 clinical trial demonstrated sustained clinical benefits across multiple efficacy measures highlighting durability of response with a median follow-up of two years ...

VSTM : 5.46 (-1.44%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Thu Apr 2, 3:05PM CDT

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted stock...

VSTM : 5.46 (-1.44%)
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 Business Wire - Tue Mar 17, 5:03PM CDT

Preclinical research with VS-7375 in combination with PRMT5 inhibitors demonstrated strong durable tumor regressions in KRAS G12D pancreatic cancer models In preclinical...

VSTM : 5.46 (-1.44%)
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers Business Wire - Tue Mar 17, 3:44PM CDT

Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial

VSTM : 5.46 (-1.44%)
Verastem: Q4 Earnings Snapshot AP - Wed Mar 4, 3:20PM CST

Verastem: Q4 Earnings Snapshot

VSTM : 5.46 (-1.44%)
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates Business Wire - Wed Mar 4, 3:01PM CST

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025 ...

VSTM : 5.46 (-1.44%)
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 Business Wire - Wed Feb 18, 6:30AM CST

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference...

VSTM : 5.46 (-1.44%)
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers Business Wire - Wed Feb 4, 6:30AM CST

Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million...

VSTM : 5.46 (-1.44%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Mon Jan 12, 3:01PM CST

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase...

VSTM : 5.46 (-1.44%)

Barchart Exclusives

Warren Buffett’s Berkshire Hathaway Is Losing Money in This Dividend Stock: Can It Work for You? Barchart - Tue Apr 28, 6:30PM CDT
Domino's Pizza has a dividend yield of 2.4%, and its dividends have risen at an annualized pace of nearly 20% over the last 10 years. Does that make the stock a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.